Novartis AG (NYSE:NVS) has earned a consensus rating of “Hold” from the eighteen research firms that are currently covering the stock. Three equities research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $92.75.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Novartis AG from a “hold” rating to a “sell” rating in a research note on Wednesday, September 21st. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Novartis AG in a research note on Tuesday, September 13th. Argus reiterated a “hold” rating on shares of Novartis AG in a research note on Thursday, August 25th. Bank of America Corp. reiterated a “hold” rating on shares of Novartis AG in a research note on Tuesday, July 12th. Finally, TheStreet upgraded shares of Novartis AG from a “hold” rating to a “buy” rating in a research note on Friday, June 24th.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Loomis Sayles & Co. L P boosted its position in shares of Novartis AG by 8.5% in the first quarter. Loomis Sayles & Co. L P now owns 5,242,948 shares of the company’s stock worth $379,800,000 after buying an additional 408,972 shares during the period. Parametric Risk Advisors LLC bought a new position in shares of Novartis AG during the first quarter worth about $829,000. Quadrature Capital Ltd bought a new position in shares of Novartis AG during the first quarter worth about $11,550,000. UBS Asset Management Americas Inc. boosted its position in shares of Novartis AG by 183.1% in the first quarter. UBS Asset Management Americas Inc. now owns 76,397 shares of the company’s stock worth $5,534,000 after buying an additional 49,415 shares during the period. Finally, Primecap Management Co. CA boosted its position in shares of Novartis AG by 0.8% in the first quarter. Primecap Management Co. CA now owns 20,938,858 shares of the company’s stock worth $1,516,811,000 after buying an additional 170,750 shares during the period. 9.78% of the stock is owned by institutional investors.
Novartis AG (NYSE:NVS) traded down 1.12% during midday trading on Wednesday, reaching $75.95. The company had a trading volume of 2,331,104 shares. The stock has a market capitalization of $180.85 billion, a PE ratio of 27.12 and a beta of 0.57. Novartis AG has a 1-year low of $69.90 and a 1-year high of $95.11. The firm’s 50 day moving average is $79.67 and its 200 day moving average is $78.98.
Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, July 19th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.05. Novartis AG had a net margin of 13.84% and a return on equity of 15.33%. The company earned $12.47 billion during the quarter, compared to the consensus estimate of $12.33 billion. During the same quarter in the prior year, the firm posted $1.25 earnings per share. On average, equities analysts anticipate that Novartis AG will post $4.72 EPS for the current fiscal year.
Novartis AG Company Profile
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.